Beyond the Fog: Why US Biolab Disclosures Raise Biosafety Questions for India

The recent release of US intelligence files documenting overseas laboratory funding highlights a critical, often-overlooked need for greater transparency in India’s own biomedical collaborations.

The shadow of the COVID-19 pandemic continues to stretch across global policy, turning what were once quiet, academic pursuits into high-stakes geopolitical puzzles. On June 12, the US Office of the Director of National Intelligence (ODNI) released a set of documents that have sent ripples through the scientific community. Disclosed by Tulsi Gabbard, these files confirm that the US has bankrolled more than 120 biological laboratories across 30 nations. For India, a country with a seven-decade history of complex, often opaque scientific partnerships with Western institutions, these revelations demand a sober look at our own oversight mechanisms.

The Scope of the Disclosure

The core of the issue lies in the nature of the research being conducted. The ODNI material confirms that some of these foreign facilities were engaged in gain-of-function (GoF) research. By definition, this involves modifying organisms to test their transmissibility, virulence, or resistance to medical interventions. Proponents argue these experiments are essential for vaccine development and pandemic preparedness. Critics, however, point to the inherent biosafety and biosecurity risks when handling pathogens that could potentially trigger a new public health crisis.

While the documents do not label these projects as misconduct, they remain incomplete. The disclosures acknowledge US funding in over 30 countries but fail to provide a granular list of every institution or nation involved. India is not explicitly mentioned in the released material, yet in the world of high-containment biological research, absence of evidence is not evidence of absence.

The Indian Context: A Legacy of Collaboration

Foreign involvement in India’s biological landscape is neither new nor inherently nefarious. Since the mid-20th century, philanthropic foundations—such as the Rockefeller Foundation—and various Western agencies have shaped our public health infrastructure. This long history of collaboration has undoubtedly bolstered India’s scientific prowess. However, when the global conversation shifts toward biological sovereignty and biosafety, the lack of a clear, public audit of current foreign-funded research in India creates a vacuum often filled by speculation rather than fact.

The Bigger Picture: Why It Matters

The real challenge for New Delhi is one of governance, not conspiracy. As international scrutiny of biological research intensifies, India must move toward a more robust framework for transparency. If the US can be pushed to release data on its global footprint, India—as a major hub for biomedical research—should take the lead in ensuring its own public health institutions are accountable to the taxpayer.

The bigger picture here is the normalization of pathogen surveillance as a tool of national security. When biosafety standards are blurred by international funding streams, the risk of a laboratory-related incident rises. For India, the imperative is clear: we need a proactive disclosure policy that clarifies the nature of foreign-supported research conducted on our soil. Transparency is the only effective shield against the misinformation that thrives when official records remain quiet.